Dyadic's Losses Widen Amid Strategic Rebrand, Public Offering Boosts Cash

TL;DR

**DYAI is burning cash faster than ever, and while the rebrand sounds good, they need to prove they can actually make money from their tech before this stock moves.**

AI Summary

DYADIC INTERNATIONAL INC reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $5,797,365, a substantial rise from $4,258,279 in the prior year. Total revenue decreased to $2,524,819 for the nine-month period in 2025, down from $2,678,013 in 2024, primarily due to a drop in license and milestone revenue from $1,425,000 to $250,000. However, grant revenue surged from zero to $1,528,224, partially offsetting the decline. Operating loss widened considerably to $5,656,912 in 2025 from $4,370,763 in 2024, driven by increased research and development expenses of $1,696,230 and higher costs of grant revenue at $1,405,562. The company completed a public offering in Q3 2025, generating $4,940,696 in net proceeds, and also saw a related party, the MAE Trust, purchase $1,000,000 of convertible notes. Cash and cash equivalents decreased to $5,834,510 from $6,506,750 at year-end 2024, but total assets increased to $11,672,757 from $9,930,275. The company rebranded to Dyadic Applied BioSolutions, signaling a strategic shift towards commercializing non-therapeutic proteins.

Why It Matters

This 10-Q reveals Dyadic's ongoing struggle with profitability, with net losses significantly increasing despite a strategic pivot and a recent public offering. For investors, the widening losses and reliance on financing, including related-party convertible notes, signal continued financial risk. The rebranding to Dyadic Applied BioSolutions and focus on non-therapeutic proteins could open new market opportunities, but the competitive landscape in biotechnology is fierce, with larger players potentially outcompeting on scale and R&D. Employees might see this as a period of transition with potential for growth in new areas, while customers could benefit from new, cost-effective protein production solutions if commercialization efforts succeed. The broader market will watch if Dyadic can translate its platform technology into sustainable revenue streams.

Risk Assessment

Risk Level: high — The company reported a net loss of $5,797,365 for the nine months ended September 30, 2025, a significant increase from $4,258,279 in the prior year, indicating a worsening financial performance. Furthermore, the company explicitly states it "expects to incur losses and have negative net cash flows from operating activities," highlighting a persistent going concern risk.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor future filings closely for concrete evidence of successful commercialization, significant revenue growth from non-therapeutic proteins, and a clear path to profitability before considering any investment.

Financial Highlights

debt To Equity

N/A

revenue

$2,524,819

operating Margin

N/A

total Assets

$11,672,757

total Debt

N/A

net Income

-$5,797,365

eps

N/A

gross Margin

N/A

cash Position

$5,834,510

revenue Growth

-5.7%

Revenue Breakdown

Key Numbers

• $5,797,365 — Net loss for nine months ended Sep 30, 2025 (Increased from $4,258,279 in 2024, indicating worsening profitability.)
• $2,524,819 — Total revenue for nine months ended Sep 30, 2025 (Decreased from $2,678,013 in 2024, primarily due to lower license revenue.)
• $1,528,224 — Grant revenue for nine months ended Sep 30, 2025 (Significant increase from $0 in 2024, partially offsetting other revenue declines.)
• $4,940,696 — Net proceeds from public offering (Received in Q3 2025, boosting financing activities.)
• $1,000,000 — Convertible notes purchased by MAE Trust (Related party financing on September 15, 2025.)
• $5,834,510 — Cash and cash equivalents as of Sep 30, 2025 (Decreased from $6,506,750 at December 31, 2024.)
• $11,672,757 — Total assets as of Sep 30, 2025 (Increased from $9,930,275 at December 31, 2024.)
• 36,187,798 — Common shares outstanding as of Nov 11, 2025 (Increased from 29,835,799 as of December 31, 2024.)

Key Players & Entities

• DYADIC INTERNATIONAL INC (company) — Registrant
• Mark Emalfarb (person) — President and Chief Executive Officer, sole beneficiary and trustee of MAE Trust
• The Francisco Trust (company) — Existing holder of more than 5% of common stock and purchaser of Convertible Notes
• MAE Trust (company) — Related party that purchased $1,000,000 of Convertible Notes
• NASDAQ Stock Market LLC (regulator) — Exchange where common stock is registered
• Securities and Exchange Commission (regulator) — Regulatory body for filings
• Jupiter, Florida (location) — Company headquarters
• Netherlands (location) — Company operations

FAQ

Risk Factors

• Continued Operating Losses and Need for Financing [high — financial]: The company reported a net loss of $5,797,365 for the nine months ended September 30, 2025, an increase from $4,258,279 in the prior year. This widening loss, coupled with a decrease in total revenue to $2,524,819 from $2,678,013, indicates ongoing financial challenges and a continued reliance on external financing to fund operations.
• Dependence on Research and Development Success [high — operational]: Operating loss widened to $5,656,912 due to increased R&D expenses of $1,696,230. The company's success is heavily dependent on the development and commercialization of its proprietary C1 gene-expression platform and related products, which are still in development stages.
• Commercialization Strategy and Market Adoption [medium — market]: The rebranding to Dyadic Applied BioSolutions signals a strategic shift towards commercializing non-therapeutic proteins. However, the success of this strategy depends on market acceptance and the ability to secure commercial partnerships and generate significant revenue from these new ventures.
• Cash Burn Rate and Liquidity [medium — financial]: Cash and cash equivalents decreased to $5,834,510 as of September 30, 2025, from $6,506,750 at year-end 2024. While the company raised $4,940,696 in net proceeds from a public offering and $1,000,000 in convertible notes, the increasing operating losses suggest a continued need for careful cash management.
• Regulatory Approval for New Products [medium — regulatory]: The commercialization of non-therapeutic proteins may involve navigating various regulatory pathways depending on the end-use applications. Delays or failures in obtaining necessary regulatory approvals could significantly impact the company's ability to generate revenue.

Industry Context

Dyadic International operates in the biotechnology sector, focusing on protein production. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The company's strategic shift towards non-therapeutic proteins places it in a segment that may have different market dynamics and competitive pressures compared to traditional biopharmaceuticals.

Regulatory Implications

The company's focus on non-therapeutic proteins may involve navigating evolving regulatory landscapes depending on the specific applications. Ensuring compliance with relevant regulations for manufacturing and commercialization will be critical for market entry and success.

What Investors Should Do

1. Monitor the company's cash burn rate and its ability to secure future funding, given the increasing net losses and decreasing cash reserves.
2. Evaluate the progress and market traction of Dyadic's commercialization strategy for non-therapeutic proteins, paying close attention to partnership developments and revenue generation.
3. Assess the impact of the increased share count on potential dilution for existing shareholders, especially if convertible notes are converted.

Key Dates

• 2025-09-30: End of Nine-Month Period — Reporting period for the 10-Q, showing increased net loss and decreased revenue, but also significant grant revenue and proceeds from a public offering.
• 2025-09-15: MAE Trust purchases $1,000,000 of convertible notes — Related party financing that provides capital to the company.
• Q3 2025: Public offering completed — Generated $4,940,696 in net proceeds, bolstering the company's cash position.
• 2025-11-11: Common shares outstanding reported as 36,187,798 — Indicates an increase in share count from 29,835,799 at year-end 2024, likely due to the recent public offering.

Glossary

C1 gene-expression platform

A proprietary technology developed by Dyadic International for producing proteins. (This platform is central to the company's strategy for developing and commercializing non-therapeutic proteins.)

Non-therapeutic proteins

Proteins that are not intended for use in treating or preventing diseases in humans or animals. (Represents the company's new strategic focus for commercialization, moving beyond its historical therapeutic applications.)

Convertible notes

Debt instruments that can be converted into shares of the issuing company's stock. (The MAE Trust purchased $1,000,000 of these notes, providing financing and potentially diluting existing shareholders if converted.)

Grant revenue

Revenue recognized from grants awarded to the company, often for research and development purposes. (A significant new source of revenue for Dyadic in the current period, partially offsetting declines in other revenue streams.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Dyadic International Inc. saw a significant increase in its net loss to $5,797,365 from $4,258,279 in the prior year, indicating worsening profitability. Total revenue declined by 5.7% to $2,524,819, primarily due to a sharp drop in license and milestone revenue, although this was partially offset by a substantial increase in grant revenue. Operating expenses rose, leading to a wider operating loss. The company did, however, strengthen its balance sheet through a public offering and related party financing, increasing total assets despite a decrease in cash and cash equivalents.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share DYAI The NASDAQ Stock Mar

Filing Documents

• form10-q.htm (10-Q) — 1162KB
• ex31-1.htm (EX-31.1) — 14KB
• ex31-2.htm (EX-31.2) — 13KB
• ex32-1.htm (EX-32.1) — 5KB
• ex32-2.htm (EX-32.2) — 5KB
• form10-q_001.jpg (GRAPHIC) — 8KB
• 0001493152-25-021908.txt ( ) — 7012KB
• dyai-20250930.xsd (EX-101.SCH) — 44KB
• dyai-20250930_cal.xml (EX-101.CAL) — 52KB
• dyai-20250930_def.xml (EX-101.DEF) — 262KB
• dyai-20250930_lab.xml (EX-101.LAB) — 441KB
• dyai-20250930_pre.xml (EX-101.PRE) — 371KB
• form10-q_htm.xml (XML) — 1162KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION 3 Item 1.

Financial Statements

Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29

OTHER INFORMATION

PART II OTHER INFORMATION Item 1 .

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30 Item 3. Defaults Upon Senior Securities 31 Item 4. Mine Safety Disclosures 31 Item 5. Other Information 31 Item 6. Exhibits 31

Signatures

Signatures 32 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This quarterly report on Form 10-Q ("Quarterly Report") contains forward-looking statements within the meaning of the federal securities laws, particularly under Item 2 "Management's Discussion and Analysis." All statements other than statements of historical fact are forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding industry prospects, future business, future results of operations or financial condition, future liquidity and capital resources, our ability to implement our agreements with third parties, management strategies, and our competitive position. Forward-looking statements generally can be identified by use of the words "expect," "should," "intend," "anticipate," "will," "project," "may," "might," "potential," or "continue" and other similar terms or variations of them or similar terminology. Dyadic International, Inc., and its subsidiaries caution readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance. Forward-looking limited to (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein production platforms and other technologies; (iii) failure to commercialize our microbial protein production platforms or our other technologies; (iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) our capital needs; (vii) changes in global economic and financial conditions; (viii) our reliance on information technology; (ix) our dependenc

View Full Filing

View this 10-Q filing on SEC EDGAR